Multiple factors cause high prescription drug prices in US

In this June 14, 2011 file photo, various prescription drugs move along the automated pharmacy assembly line at Medco Health Solutions in Willingboro, N.J.  (Matt Rourke/AP, 2011)

In this June 14, 2011 file photo, various prescription drugs move along the automated pharmacy assembly line at Medco Health Solutions in Willingboro, N.J. (Matt Rourke/AP, 2011)

TRENTON, N.J. — Sticker-shocked patients increasingly wonder why prices for prescription drugs continue to rise in the U.S.

The issue heated up this week on news that Turing Pharmaceuticals raised the price of Daraprim, the only approved treatment for a rare, life-threatening parasitic infection, by more than 5,000 percent to $750 a pill.

Medical groups blasted the increase, and Democratic presidential candidate Hillary Clinton called it “price gouging.” Turing’s CEO, former hedge fund manager Martin Shkreli, later said he’d make “a serious price adjustment.”

But the issue goes beyond a single company or drug.

From 2008 through 2014, average prices for the most widely used brand-name drugs jumped 128 percent, according to prescription benefit manager Express Scripts Holding Co. In 2014, it estimated that total U.S. prescription drug spending increased 13 percent. Reasons include increasing research costs, insufficient competition and drug shortages.

Pharmaceutical and biotech industry groups say prescription medicines save money by preventing costly complications and hospitalizations and have long accounted for just 10 percent of annual U.S. health care spending. That could change, because many new drugs for cancer, hepatitis C and rare disorders carry list prices of $100,000 or more for a year or course of treatment.

For patients with insurance requiring them to pay a significant percentage of medication costs, the priciest drugs can be unaffordable. Higher prices can trickle down even to those who now have flat copayments, such as $30 per prescription, because as insurance plans incur higher costs, they usually increase the share beneficiaries pay in subsequent years.

While it’s clear drug prices are rising, many patients don’t understand why. Here are six of the top reasons:


The U.S. government doesn’t regulate prices, unlike many countries where government agencies negotiate prices for every drug. In the U.S., drugmakers set wholesale prices based mostly on what competing brand-name drugs cost and whether their new drug is better, said Les Funtleyder, healthcare portfolio manager at E Squared Asset Management.


Patents last longer than in other countries, usually giving a drug’s maker exclusivity that prevents competition for 20 years from when the patent is issued. Because patents are filed while drugs are still in testing, that clock starts ticking long before the drug goes on sale. Typically, new drugs end up with a monopoly for roughly a dozen years.

Their makers generally increase their prices every year, by about 5 percent or more. Those increases add up, and become bigger as the expiration of the patent approaches.


For many drugs, there isn’t enough competition to hold down prices. Many older generic drugs were priced too low to be very profitable, so some drugmakers stopped making them. Once only one or two companies make a drug, the price usually shoots up.

For older, brand-name drugs that treat conditions too rare to attract multiple manufacturers, the sole maker has a de facto monopoly.

Funtleyder noted the large backlog of generic drugs awaiting U.S. regulatory approval means that for some off-patent drugs, only one or two generic versions have been approved. That limits reductions from the brand-name drug’s price.

Scores of drugs, mostly older, once-cheap generics, have been in short supply over the last decade. Reasons include raw material shortages and manufacturing deficiencies involving dirty factories, pills containing the wrong amount of active ingredient and other serious problems, particularly at factories in India. Those trigger production shutdowns or temporary bans on their sale in the U.S.

Also, several drugmakers recently have been buying rights to older drugs, then hiking the price, as Turing did with Daraprim.


Many new drugs are for rare conditions or cancer subtypes involving a particular genetic mutation, so they might help just thousands or hundreds of patients. To recoup research and development costs, drugmakers set very high prices, though they offer many patients financial assistance.


Research is becoming increasingly expensive. Industry groups say it can take about a decade and well over $1 billion to get a new drug approved, though that includes development costs for the many drugs that don’t work out.

The most-exorbitant new drugs are biologics, produced by living cells under very precise conditions, which costs far more than mixing chemicals to make pills.


After a huge wave of patent expirations from 2011 through 2013 that brought generic versions of drugs taken daily by millions of patients, the number of popular drugs going off patent has declined. That’s contributed to total U.S. spending on medicine rising.

pharmaceuticalsprescription drugsUS

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at

Just Posted

San Francisco Police officers speak with people while responding to a call outside a market on Leavenworth Street in the Tenderloin on Tuesday, June 22, 2021. (Kevin N. Hume/The Examiner)
SFPD makes the case for more officers, citing Walgreens video

Most of us have seen the video. It shows a man filling… Continue reading

A 14-Mission Muni bus heads down Mission Street near Yerba Buena Gardens. (Kevin N. Hume/S.F. Examiner)
Pandemic experiments morph into long-term solutions for SF transit agency

The streets of San Francisco became real-time laboratories for The City’s public… Continue reading

San Francisco Public Bank Coalition advocates rallied on Feb. 5, 2019 as the Board of Supervisors considered supporting the creation of a public banking charter. (Kevin N. Hume/The Examiner)
Debate reignites over San Francisco’s first public bank

Prior to the COVID-19 pandemic, momentum was building for San Francisco to… Continue reading

Apprenticeship instructor Mike Miller, center, demonstrates how to set up a theodolite, a hyper-sensitive angle measuring device, for apprentices Daniel Rivas, left, Ivan Aguilar, right, and Quetzalcoatl Orta, far right, at the Ironworkers Local Union 377 training center in Benicia on June 10, 2021. (Courtesy Anne Wernikoff/CalMatters)
California’s affordable housing crisis: Are labor union requirements in the way?

By Manuela Tobias CalMatters California lawmakers introduced several bills this year that… Continue reading

Mayor London Breed spoke at the reopening of the San Francisco Public Library main branch on April 20. (Sebastian Miño-Bucheli/Special to The Examiner)
SF reopening more libraries through the summer

After a handful of San Francisco public libraries reopened last month for… Continue reading

Most Read